INZY insider transaction filings
Inozyme Pharma, Inc. — 31 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-07-03. Screen INZY transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for INZY between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Inozyme Pharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-07-03 | 4 | Subramanian Sanjay — SVP, CFO & Head of BD | Code (U): 39,701 @ $4 · Disposition to issuer (D): 38,500 (derivative) · Disposition to issuer (D): 180,000 (derivative) · Disposition to issuer (D): 135,000 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Winton Matthew — COO | Code (U): 21,743 @ $4 · Disposition to issuer (D): 41,500 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Sullivan Lynne Marie — Director | Disposition to issuer (D): 28,368 (derivative) | EDGAR |
| 2025-07-03 | 4 | Treco Douglas A — CEO & Chairman, Director | Code (U): 43,861 @ $4 · Disposition to issuer (D): 150,000 (derivative) · Disposition to issuer (D): 86,979 (derivative) · Disposition to issuer (D): 400,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Bolte Axel — Director | Code (U): 423,926 @ $4 · Disposition to issuer (D): 234,176 (derivative) · Disposition to issuer (D): 159,187 (derivative) | EDGAR |
| 2025-07-03 | 4 | Hopfner Robert Lorne — Director | Code (U): 2,923,110 @ $4 · Code (U): 1,571,741 @ $4 | EDGAR |
| 2025-06-27 | 4 | Winton Matthew — COO | Grant/award (A): 14,355 @ $0.74 | EDGAR |
| 2025-06-27 | 4 | Subramanian Sanjay — SVP, CFO & Head of BD | Grant/award (A): 6,813 @ $0.74 | EDGAR |
| 2025-06-27 | 4 | Treco Douglas A — CEO & Chairman, Director | Grant/award (A): 2,815 @ $0.74 | EDGAR |
| 2025-05-20 | 4 | Bolte Axel — Director | Option exercise (M): 152,823 @ $0.98 · Option exercise (M): 4,407 @ $0.98 · Option exercise (M): 152,823 (derivative) @ $0 · Option exercise (M): 4,407 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Treco Douglas A — CEO & Chairman, Director | Option exercise (M): 25,000 · Sale (S): 8,819 @ $0.89 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Winton Matthew — COO | Grant/award (A): 2,490 @ $0.77 | EDGAR |
| 2025-04-02 | 4 | Subramanian Sanjay — SVP, CFO & Head of BD | Grant/award (A): 2,490 @ $0.77 | EDGAR |
| 2025-03-17 | 4 | Subramanian Sanjay — SVP, CFO | Grant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 38,500 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Winton Matthew — COO | Grant/award (A): 145,000 (derivative) @ $0 · Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Treco Douglas A — CEO, Director | Grant/award (A): 400,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-10-07 | 4 | Harris Erik — Director | Grant/award (A): 56,000 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Winton Matthew — COO | Grant/award (A): 1,710 @ $4.45 | EDGAR |
| 2024-10-03 | 4 | Treco Douglas A — CEO, Director | Grant/award (A): 1,710 @ $4.45 | EDGAR |
| 2024-06-20 | 4 | Sullivan Lynne Marie — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Bhagat Sarah M — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Edwards Martin — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Bolte Axel — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Hopfner Robert Lorne — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Mathers Edward T — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | DIAZ REINALDO M — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Winton Matthew — COO | Grant/award (A): 3,188 @ $3.33 | EDGAR |
| 2024-04-03 | 4 | Treco Douglas A — CEO, Director | Option exercise (M): 25,000 · Sale (S): 7,523 @ $6.94 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Winton Matthew — COO | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Subramanian Sanjay — SVP, CFO | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Treco Douglas A — CEO, Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Inozyme Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-01 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-05-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-14 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition ? 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-10 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-24 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-07 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INZY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →